Qilu Pharmaceutical Co., Ltd.

Qilu Pharmaceutical Co., Ltd. logo
🇨🇳China
Ownership
Private, Subsidiary
Established
1992-08-21
Employees
10K
Market Cap
-
Website
http://www.qilu-pharma.com

Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR

Not Applicable
Not yet recruiting
Conditions
Interventions
First Posted Date
2017-12-22
Last Posted Date
2017-12-22
Lead Sponsor
Qilu Pharmaceutical Co., Ltd.
Target Recruit Count
50
Registration Number
NCT03381430
Locations
🇨🇳

China-Japan Friendship Hospital, Beijing, China

Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD

First Posted Date
2017-10-17
Last Posted Date
2019-04-11
Lead Sponsor
Qilu Pharmaceutical Co., Ltd.
Target Recruit Count
48
Registration Number
NCT03312283
Locations
🇨🇳

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

First Posted Date
2017-08-30
Last Posted Date
2020-08-03
Lead Sponsor
Qilu Pharmaceutical Co., Ltd.
Target Recruit Count
100
Registration Number
NCT03267654
Locations
🇨🇳

Shanghai Pulmonary Hospital;, Shanghai, Shanghai, China

A Study to Investigate the Safety, Efficacy and Pharmacokinetic Profile of Multiple Doses of QL-007 in Chronic Hepatitis B Patients

Phase 1
Conditions
Interventions
First Posted Date
2017-08-09
Last Posted Date
2018-07-16
Lead Sponsor
Qilu Pharmaceutical Co., Ltd.
Target Recruit Count
18
Registration Number
NCT03244085
Locations
🇳🇿

P3 Research, Wellington, New Zealand

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer

First Posted Date
2017-06-22
Last Posted Date
2017-06-22
Lead Sponsor
Qilu Pharmaceutical Co., Ltd.
Target Recruit Count
15
Registration Number
NCT03195569
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tainjin, China

Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer

First Posted Date
2017-05-30
Last Posted Date
2018-08-24
Lead Sponsor
Qilu Pharmaceutical Co., Ltd.
Target Recruit Count
535
Registration Number
NCT03169335
Locations
🇨🇳

Tianjin Chest hospital, Tianjin, China

🇨🇳

Shanghai Chest hospital, Shanghai, China

A Phase Ib Study of Selatinib Ditosilate Tablets in Patients With Advanced Breast Cancer

First Posted Date
2013-08-30
Last Posted Date
2013-08-30
Lead Sponsor
Qilu Pharmaceutical Co., Ltd.
Target Recruit Count
24
Registration Number
NCT01931943
Locations
🇨🇳

Cancer Institute and Hospital,Chinese Academy of Medical Sciences, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath